The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).
 
Farhad Ravandi
Honoraria - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Jazz Pharmaceuticals; Novartis; Pfizer; Syros Pharmaceuticals; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; AstraZeneca; Bristol Myers Squibb; Celgene; Certara Inc; Jazz Pharmaceuticals; Syros Pharmaceuticals; Taiho Oncology
Research Funding - Amgen; Astex Pharmaceuticals; Biomea Fusion; Bristol-Myers Squibb; Cellerant; Macrogenics; Prelude Therapeutics; Selvita; Syros Pharmaceuticals; Taiho Oncology; Xencor
 
Ashwin Kishtagari
Research Funding - Biomea Fusion
 
Hetty E Carraway
Consulting or Advisory Role - BMS; Jazz Pharmaceuticals; Novartis
Speakers' Bureau - Agios; BMSi; Jazz Pharmaceuticals; Novartis; Stemline Therapeutics
Research Funding - Celgene
Travel, Accommodations, Expenses - Jazz Pharmaceuticals; Novartis
Other Relationship - Abbvie; Astex Pharmaceuticals; Syndax; Takeda
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Agios; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical
Speakers' Bureau - Amgen; Astellas Pharma; Bristol-Myers Squibb; Jazz Pharmaceuticals; Kite, a Gilead company; Sanofi; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Arog; Astellas Pharma; Bristol-Myers Squibb/Celgene; Celator; Constellation Pharmaceuticals; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Takeda; Tolero Pharmaceuticals; Trovagene
 
Steve Morris
Employment - Greenfire Bio
 
Alexandru Cacovean
Employment - Biomea Fusion; Iovance Biotherapeutics
Stock and Other Ownership Interests - Biomea Fusion
Travel, Accommodations, Expenses - Biomea Fusion
 
Bhagyashree (Kelshikar) Yadav
Employment - Biomea Fusion; Iovance Biotherapeutics
Stock and Other Ownership Interests - Biomea Fusion; Iovance Biotherapeutics
Travel, Accommodations, Expenses - Biomea Fusion
 
Thomas Butler
Employment - Biomea Fusion
Leadership - Biomea Fusion
Stock and Other Ownership Interests - Biomea Fusion
Patents, Royalties, Other Intellectual Property - Biomea Fusion
Travel, Accommodations, Expenses - Biomea Fusion
 
Jeffrey E. Lancet
Stock and Other Ownership Interests - Arvinas (I)
Consulting or Advisory Role - Abbvie; BerGenBio; Bristol-Myers Squibb/Celgene; Daiichi Sankyo; ElevateBio; Jazz Pharmaceuticals; Millennium; Novartis; Servier/Pfizer